Alan Au is a partner in our Corporate team based in our Hong Kong office. He advises PRC and international clients on a broad range of corporate transactions involving privatisations, initial public offerings, mergers and acquisitions, private and public equity and debt offering, SPAC and De-SPAC transactions, pre-IPO financing, joint ventures and share option and award schemes. Alan has a strong science and pharmaceutical background and has extensive experience in handling biotech companies’ corporate transactions and IPOs. His major clients include bulge bracket banks, PRC and international law firms, listed companies and private equi ...
Alan Au is a partner in our Corporate team based in our Hong Kong office. He advises PRC and international clients on a broad range of corporate transactions involving privatisations, initial public offerings, mergers and acquisitions, private and public equity and debt offering, SPAC and De-SPAC transactions, pre-IPO financing, joint ventures and share option and award schemes.
Alan has a strong science and pharmaceutical background and has extensive experience in handling biotech companies’ corporate transactions and IPOs. His major clients include bulge bracket banks, PRC and international law firms, listed companies and private equity institutions.
Prior to joining us, Alan was a senior corporate lawyer at Ogier. During his legal career, he has also worked at Fangda Partners, Shearman & Sterling, Bird & Bird, Sidley Austin and Robertsons. Before qualifying as a lawyer in 2012, Alan was a medical specialist at GlaxoSmithKline and Stiefel Laboratories.
Alan is fluent in Mandarin, English and Cantonese.